Phenylbutyl isoselenocyanate (ISC-4) is an Akt inhibitor with demonstrated preclinical efficacy against melanoma and colon cancer. In this study, we sought to improve the clinical utility of ISC-4 by identifying a synergistic combination with FDA-approved anti-cancer therapies, a relevant and appropriate disease setting for testing, and biomarkers of response. We tested the activity of ISC-4 and 19 FDA-approved anticancer agents, alone or in combination, against the SW480 and RKO human colon cancer cell lines. A synergistic interaction with cetuximab was identified and validated in a panel of additional colon cancer cell lines, as well as the kinetics of synergy. ISC-4 in combination with cetuximab synergistically reduced the viability of human colon cancer cells with wild-type but not mutant KRAS genes. Further analysis revealed that the combination therapy cooperatively decreased cell cycle progression, increased caspase-dependent apoptosis, and decreased phospho-Akt in responsive tumor cells. The synergism between ISC-4 and cetuximab was retained independently of acquired resistance to 5-FU in human colon cancer cells. The combination demonstrated synergistic anti-tumor effects in vivo without toxicity and in the face of resistance to 5-FU. These results suggest that combining ISC-4 and cetuximab should be explored in patients with 5-FU-resistant colon cancer harboring wild-type KRAS.
References
[1]
Zhang Y (2004) Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 555: 173–190.
[2]
Keum Y-S, Jeong W-S, Tony Kong AN (2004) Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 555: 191–202.
[3]
Nguyen N, Sharma A, Nguyen N, Sharma AK, Desai D, et al. (2011) Melanoma Chemoprevention in Skin Reconstructs and Mouse Xenografts Using Isoselenocyanate-4. Cancer Prevention Research 4: 248–258.
[4]
Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, et al. (2009) Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clinical Cancer Research 15: 1674–1685.
[5]
Sharma AK, Kline CL, Berg A, Amin S, Irby RB (2011) The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model. Clinical Cancer Research 17: 4474–4483.
[6]
Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, et al. (2008) Synthesis and Anticancer Activity Comparison of Phenylalkyl Isoselenocyanates with Corresponding Naturally Occurring and Synthetic Isothiocyanates. Journal of Medicinal Chemistry 51: 7820–7826.
[7]
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10–29.
[8]
Chou T-C (2006) Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews 58: 621–681.
[9]
Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Molecular Cancer Therapeutics 5: 2606–2612.
[10]
Lievre A, Bachet J-B, Le Corre D, Boige V, Landi B, et al. (2006) KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Res 66: 3992–3995.
[11]
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine 359: 1757–1765.
[12]
Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, et al. (2008) Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. The Prostate 68: 965–974.
[13]
Bunz F, Hwang P, Torrance C, Waldman T, Zhang Y, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. JCI 104: 263–269.
[14]
Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, et al. (2007) Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab. Clinical Cancer Research 13: 7432–7440.
[15]
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New England Journal of Medicine 351: 337–345.
[16]
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532–536.
[17]
Allen JE, El-Deiry WS (2010) Circulating Tumor Cells and Colorectal Cancer. Current Colorectal Cancer Reports 6: 212–220.
[18]
Faltas B, Zeidan A, Peters K, Das A, Joudeh J, et al. (2011) Identifying Circulating Tumor Stem Cells That Matter: The Key to Prognostication and Therapeutic Targeting. Journal of Clinical Oncology 29: 2946–2947.
